Lifordi Immunotherapeutics Presents Promising Preclinical Data for Targeted Autoimmune Treatment
TL;DR
Lifordi's LFD-200 ADC technology offers a competitive edge by delivering steroid efficacy without systemic toxicity, potentially capturing significant autoimmune treatment market share.
Lifordi's LFD-200 uses antibody drug conjugate technology to selectively deliver glucocorticoids to immune cells through VISTA targeting, achieving sustained anti-inflammatory effects without systemic toxicity.
Lifordi's LFD-200 could improve autoimmune patients' quality of life by providing safer, less frequently dosed steroid treatments with reduced side effects.
Lifordi's innovative antibody drug conjugate delivers steroids directly to immune cells, achieving targeted treatment effects without the typical systemic toxicity concerns.
Found this article helpful?
Share it with your network and spread the knowledge!
Lifordi Immunotherapeutics will present new preclinical data showing its lead antibody drug conjugate candidate LFD-200 achieves targeted delivery of glucocorticoids to immune cells without evidence of systemic toxicity. The findings from multiple non-human primate studies demonstrate that LFD-200 provides sustained anti-inflammatory effects while avoiding the safety concerns typically associated with steroid treatments.
The data, to be presented at the American College of Rheumatology Convergence 2025 meeting in Chicago, shows LFD-200 selectively delivers its glucocorticoid payload to immune tissues and inhibits ex vivo induced inflammatory cytokines. This targeted approach represents a significant advancement in autoimmune treatment, as current glucocorticoid therapies often cause widespread side effects due to their systemic nature.
According to the company's research, LFD-200 maintained a favorable safety profile at clinically relevant doses while providing sustained anti-inflammatory activity. The antibody drug conjugate specifically targets immune cells using a highly internalized cell surface membrane protein called VISTA, allowing precise delivery of the therapeutic payload to the cells driving inflammatory responses.
The potential impact of this technology extends beyond LFD-200, as Lifordi has applied its novel drug delivery platform to other payload types including small molecules, antisense oligonucleotides, and siRNA. This broader platform approach could revolutionize treatment for various autoimmune and inflammatory conditions by enabling targeted delivery of diverse therapeutic agents.
Lifordi Immunotherapeutics, which is developing antibody drug conjugates specifically for autoimmune and inflammatory disorders, has advanced LFD-200 into Phase 1 clinical trials. The company's progress is supported by funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture. Additional information about the company's research and development programs can be found at https://www.lifordi.com.
The presentation of these preclinical data at the ACR Convergence 2025 meeting marks an important milestone in the development of targeted therapies for autoimmune diseases. If successful in human trials, LFD-200 could provide patients with a safer, less frequently dosed glucocorticoid treatment option, addressing a significant unmet need in autoimmune disease management where current steroid treatments often require difficult trade-offs between efficacy and safety concerns.
Curated from Reportable
